IQVIA (NYSE:IQV) 2026 Conference February 26, 2026 11:00 AM ET Company ParticipantsMike Fedock - Incoming CFORon Bruehlman - Outgoing CFOConference Call ParticipantsPatrick Donnelly - Managing Director, Tools and Diagnostics/CRO AnalystPatrick DonnellyI think we can look to get started. Thank you, everybody, for joining us, we're here at the Citi MedTech Access Day. I'm Patrick Donnelly, the tools and diagnostics CROs analyst here. Happy to have a unique opportunity here with Ron and Mike, incoming CFO, out ...

Financial Data and Key Metrics Changes - Revenue in Q4 2025 was $708.5 million, representing a year-over-year increase of 32% [5][6] - Full year 2025 revenue was $2.53 billion, a 20% increase from 2024 [5][6] - EBITDA for Q4 2025 was $160.2 million, up 20% from $133.5 million in Q4 2024 [6][7] - Full year EBITDA was $557.7 million, a 16.1% increase from the prior year [7] - Net income for Q4 2025 was $135.1 million, a 15.5% increase compared to $117 million in the prior year [7][8] - Full year net income was $451.1 million, an 11.6% increase from $404.4 million in 2024 [8] Business Line Data and Key Metrics Changes - Net new business awards entering backlog in Q4 increased 39.1% year-over-year to $736.6 million [5] - Ending backlog as of December 31, 2025, was approximately $3 billion, a 4.3% increase from the prior year [5] - Backlog conversion rate in Q4 was 23.6% of beginning backlog [5] Market Data and Key Metrics Changes - Cancellations were elevated in Q4, resulting in the highest backlog cancellations in over a year [4] - The net book-to-bill ratio was 1.04, lower than anticipated due to increased cancellations [4] Company Strategy and Development Direction - The company rates the overall business environment as adequate and improving [4] - There is an expectation for accelerated hiring in 2026, with a focus on mid to high single-digit growth [15] - The company anticipates a shift in the therapeutic area concentration, with metabolic trials expected to normalize as a percentage of revenue [31] Management's Comments on Operating Environment and Future Outlook - Management noted that the business environment remains reasonably good, with RFPs up slightly [18] - There is no significant change in decision-making or project progression despite elevated cancellations [55] - The company does not foresee a long-term risk from the concentration in the metabolic area [31] Other Important Information - Full year 2026 total revenue is expected to be in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 [9] - The company plans to maintain a focus on improving efficiency through technology and AI applications [65] Q&A Session Summary Question: What is embedded in your guidance for revenue growth excluding pass-throughs? - The company does not provide guidance on direct service revenue but expects reimbursable costs to be consistent with previous expectations [12][13] Question: What do you expect headcount growth to be in 2026? - The company anticipates hiring in 2026 to be above 25 levels, in the mid to high single-digit growth area [14] Question: Can you unpack the business environment and RFP activity? - The business environment is reasonably good, with RFPs up slightly, but cancellations led to missing expectations [18] Question: Can you provide details on cancellations? - Cancellations were widespread and not concentrated in any single project or client [24][22] Question: How do you view the competitive landscape? - The competitive landscape remains stable, with no significant changes in dynamics observed [59] Question: What are your thoughts on AI and its impact? - The company believes it is too early to determine the long-term impact of AI, with expectations for gradual changes [51]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested Jiangsu Dingtai Pharmaceutical Research (Dingtai Yao Yan) to provide supplementary explanations regarding equity changes and other matters as part of its application for listing on the Hong Kong Stock Exchange [1][2][3] Group 1: Equity Changes - The CSRC requires Dingtai Yao Yan to clarify the pricing basis for past capital increases and equity transfers, including whether actual contributions were made and if there are any unfulfilled obligations or defects in the contribution methods [1] - The company must provide updates on the overseas investment procedures related to the establishment of Hong Kong Dingtai and the ODI procedures concerning the investment in Xellar Ltd [1] - A review of historical shareholding arrangements and the involvement of external advisors in employee stock ownership plans is mandated to ensure compliance and identify any potential conflicts of interest [1][2] Group 2: Shareholder Situation - Dingtai Yao Yan is required to justify the reasonableness of the share prices for new shareholders over the past 12 months and to clarify any discrepancies in these prices [2] - The company must confirm whether shares held by four shareholders obtained through the share transfer system are subject to pledges, freezes, or other rights defects [2] Group 3: Business Operations - The company needs to detail its business scope, which includes medical research, gene diagnosis and treatment technology development, and breeding of protected wildlife, ensuring that it has the necessary qualifications and complies with foreign investment policies [2] - A legal opinion is required to confirm whether the company or its subsidiaries fall under any prohibitive circumstances for overseas issuance and listing as per regulatory guidelines [2][3] Group 4: Listing and Full Circulation - Dingtai Yao Yan must explain any inconsistencies between the proposed listing plan and the materials submitted, including the prospectus [3] - The company is also required to disclose the status of shares held by shareholders participating in the "full circulation" and whether these shares are subject to any rights defects [3] - Details regarding the company's previous listing on the National Equities Exchange and Quotations (NEEQ) and the reasons for its termination, as well as plans for A-share listing, must be provided [3]

Core Insights - The successful IPO of Insilico Medicine (stock code: 3696.HK) on the Hong Kong Stock Exchange marks the largest fundraising in the Hong Kong biopharmaceutical sector this year, highlighting the capital market's recognition of AI-driven drug development [1] - Insilico Medicine's partnership with MediXis (stock code: 688202.SH) has gained new attention and industry imagination, emphasizing the critical role of MediXis as a preclinical research service provider in the AI drug development wave [1] Group 1: AI and CRO Integration - The collaboration between Insilico Medicine and MediXis has transformed the drug development paradigm, with MediXis demonstrating efficient and stable delivery capabilities in various tumor projects, enabling rapid clinical progression of AI-discovered molecules [2] - This partnership represents a deep integration of service procurement and technical processes, with Insilico leveraging its Pharma.AI platform for breakthroughs in target discovery and molecular generation, while MediXis provides comprehensive preclinical services [2] Group 2: Expansion of Services and Capabilities - By mid-2025, MediXis has empowered approximately 588 IND approvals, with projects in collaboration with Insilico serving as successful examples of the "AI-driven development + professional CRO execution" model, enhancing both companies' efficiency and experience in AI drug development [3] - MediXis has expanded its AI drug discovery service platform, exploring new therapies such as PROTAC, ADC, nucleic acid drugs, and cell and gene therapies, showcasing its comprehensive strategic layout and capability evolution [4] Group 3: Industry Leadership and Global Strategy - MediXis has solidified its industry-leading position through systematic capability building, achieving breakthroughs in service granularity, technological foresight, compliance systems, and global expansion [4] - The company has successfully obtained various GLP qualifications and enhanced its competitiveness in international preclinical research, with a growing proportion of revenue from overseas clients and increased new order amounts [5] Group 4: Future Outlook - The successful listing of Insilico Medicine signifies a milestone in the capitalization and industrialization of AI drug development, positioning MediXis as an indispensable verification and efficiency engine within the AI drug development ecosystem [6] - As the demand for high-efficiency and high-reliability preclinical research services continues to grow, MediXis is well-positioned to strengthen its leading role as a preclinical research enabler by deepening collaborations with cutting-edge technology companies like Insilico [6]

Core Viewpoint - Shanghai Yinos Biotechnology Co., Ltd. has been awarded the "2025 Most Socially Responsible Listed Company Award" for its outstanding practices in social responsibility and professional service capabilities, highlighting its deep accumulation and core value in the CRO professional segment [1][3] Company Overview - Yinos is a comprehensive R&D service (CRO) company specializing in non-clinical research services for biomedicine, adhering to the core values of "science-led, quality-first, integrity, and win-win cooperation" [3] - The company focuses on major national biomedicine development needs and plays a significant role in drug evaluation services, contributing to the high-quality development of the biomedicine industry [3] Business Performance - In Q3 2025, Yinos achieved operating revenue of 195 million yuan, a quarter-on-quarter increase of 17.71%, maintaining a steady growth trend [4] - The company saw a 29.37% year-on-year increase in new order amounts, with significant growth in new drug clinical trial applications (IND) and new drug marketing applications (NDA), which rose by 30.71% and 23.06% respectively [4] Market Position and Strategy - Yinos is positioned as a leading enterprise in the CRO industry, benefiting from a high-growth cycle and possessing technical advantages that meet high-end demand across the entire service chain [4] - The company has established a non-clinical drug metabolism platform compliant with ICH, FDA, and NMPA standards, enhancing its capabilities in radiolabeled isotopes and imaging evaluation research [4] Innovation and International Expansion - Yinos is continuously advancing frontier technologies, particularly in small nucleic acid drugs and CAR-T cell therapy, establishing a comprehensive technical service matrix [5][6] - The company has expanded its international market presence, with significant growth in new order amounts from overseas, enhancing its brand influence and recognition [6] Future Outlook - The award received is not only a recognition of past achievements but also an expectation for future development, as CRO companies play an increasingly important role in new drug development [6] - Yinos aims to leverage this award to strengthen its professional advantages while actively fulfilling social responsibilities, contributing to the high-quality development of China's biomedicine industry [6]

Financial Data and Key Metrics Changes - The company reported a book-to-bill ratio of 1.13 times in Q3, indicating a recovery from Q2 [1][2] - The company has improved cash flow and reduced Days Sales Outstanding (DSO), focusing on the fundamentals of order to cash [38] Business Line Data and Key Metrics Changes - The company has seen an increase in RFP volumes, particularly from new clients across various phases of clinical trials, including small biotech and large pharma [5][6] - The phase I business has continued to grow, contributing positively to overall revenue [48][62] Market Data and Key Metrics Changes - The biotech funding environment is showing signs of improvement, with a cautious optimism among clients regarding capital availability for trials [12][13] - The company has not been significantly affected by cancellations, maintaining historical norms, while competitors with high exposure to specific studies have faced challenges [84][85] Company Strategy and Development Direction - The company is focused on transitioning to a fully independent operation, emphasizing new systems, processes, and talent to drive growth [18][19] - The strategy includes optimizing project management and resource allocation to enhance operational excellence [26][27] - The company aims to maintain a disciplined approach to pricing, avoiding aggressive bidding strategies that compromise margins [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the next two and a half years, highlighting a return to growth and improved market conditions [17][19] - The leadership transition has been positively received, with customer engagement improving significantly [2][3] Other Important Information - The company has divested non-core businesses, allowing for a 30% reduction in debt and a focus on improving leverage [38][39] - Cost-saving initiatives are on track, with a target of $150 million in gross savings, and a significant portion being reinvested in employees [52][53] Q&A Session Summary Question: Can you discuss the customer sentiment and changes from Q2 to Q3? - Management noted that customer hesitation around leadership transition dissipated quickly, leading to improved engagement and execution [2][3] Question: What metrics can you provide regarding new clients and RFP volumes? - The company reported increased RFP volumes and a diverse mix of new clients, including small biotech and large pharma [5][6] Question: How is the company addressing pricing pressures in the market? - Management stated that they have not pursued aggressive pricing strategies and have walked away from unprofitable work [30][31] Question: What is the outlook for debt repayment and capital allocation? - The company plans to prioritize debt repayment while also considering small targeted investments for organic growth [38][39] Question: How does the company view the current cancellations trend? - Cancellations have remained within historical norms, with no significant exposure to high-risk studies that have affected competitors [84][85] Question: Is there a sense of increased willingness among clients to move forward with trials? - Management indicated that recent policy changes have lifted some reluctance, allowing clients to proceed with trials more confidently [86][88]

Financial Data and Key Metrics Changes - The company reported a book-to-bill ratio of 1.13 times in Q3, indicating a recovery from Q2 [1][2] - There was a significant improvement in customer sentiment and engagement, particularly following a leadership transition [2][3] Business Line Data and Key Metrics Changes - The company has seen an increase in RFP volumes, particularly from new clients across various sectors, including small biotech and large pharma [5][6] - The diversity of clients has expanded, with a focus on engaging more effectively with new customers [5] Market Data and Key Metrics Changes - The biotech funding environment is showing signs of improvement, although it has not yet returned to pre-2018 levels [12][13] - The company is experiencing a normalization in cancellations, consistent with historical norms, and is not heavily exposed to sectors facing significant cancellations [84][85] Company Strategy and Development Direction - The company is transitioning into a fully independent entity, focusing on operational excellence and project-level profitability [18][19] - There is a commitment to not pursue aggressive pricing strategies, instead focusing on sustainable margins and project profitability [30][32] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the market, noting a return to growth and improved customer engagement [19][12] - The leadership emphasized the importance of project-level management and profitability, leveraging new systems and processes to enhance operational efficiency [72][73] Other Important Information - The company has successfully reduced its debt by approximately 30% since the spin-off and continues to prioritize debt repayment alongside targeted investments for growth [38][39] - Cost-saving initiatives are on track, with a goal of achieving $150 million in gross savings, of which a portion is being reinvested in employee development [52][53] Q&A Session Summary Question: Can you discuss the customer sentiment and engagement changes from Q2 to Q3? - Management noted that customer hesitation due to leadership transition dissipated quickly, leading to improved engagement and a bounce back in business [2][3] Question: What metrics can you provide regarding new clients and RFP volumes? - The company reported increased RFP volumes and a diverse mix of new clients, including both small biotech and large pharma [5][6] Question: How is the company addressing pricing pressures in the market? - Management stated that they are not pursuing aggressive pricing strategies and are focused on maintaining healthy margins [30][32] Question: What is the outlook for the biotech funding environment? - There are signs of improvement in funding, but it has not yet returned to the levels seen in 2018 and 2019 [12][13] Question: How is the company managing its debt and capital allocation? - The company has reduced debt significantly and is focused on further debt repayment while also considering small targeted investments for growth [38][39]

Financial Data and Key Metrics Changes - The company reported a book-to-bill ratio of 1.13 times in Q3, indicating a recovery from Q2 [3] - The management highlighted a significant improvement in cash flow and a reduction in debt, having paid down approximately $77 million of senior secured notes [38][39] Business Line Data and Key Metrics Changes - The company has seen an increase in RFP volumes, particularly from new clients across various phases of clinical trials, including small biotech and large pharma [5][6] - The phase one business has continued to grow, contributing positively to the overall performance [50] Market Data and Key Metrics Changes - The biotech funding environment is showing signs of improvement, although it has not yet returned to the levels seen in 2018 and 2019 [12] - The company has not experienced significant cancellations, maintaining a consistent cancellation rate in line with historical norms [85][86] Company Strategy and Development Direction - The company is focusing on operational excellence, project management, and financial discipline to enhance profitability and growth [20][21] - A bespoke go-to-market strategy is being implemented to better serve biotech clients, emphasizing the right resource allocation and project-level profitability [10][11][72] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the market, noting a return to growth and improved customer sentiment following a leadership transition [2][3] - The company is committed to continuous improvement in project management and operational efficiency, with a focus on long-term growth [20][21][72] Other Important Information - The company has set a revenue guidance of $2.7-$2.75 billion for the year, with a focus on maintaining margins despite the impact of pass-throughs [58][60] - Cost-saving initiatives are on track, with a target of $150 million in gross savings, of which a portion is being reinvested in employee development [52][53] Q&A Session Summary Question: How does the company view the current debt situation? - The company has focused on debt repayment since the spin-off, successfully reducing debt by approximately 30% and continuing to prioritize debt pay down alongside targeted investments for growth [38][39][44] Question: What is the company's approach to pricing in the competitive landscape? - The company has chosen not to engage in aggressive pricing strategies, focusing instead on maintaining healthy margins and project profitability [30][31][32] Question: How does the company plan to manage operational changes moving forward? - Management emphasized the importance of project-level profitability and the need for the right systems and processes to manage projects effectively [72][73][74] Question: What is the outlook for cancellations in the industry? - The company has maintained a consistent cancellation rate, with no significant deviations from historical norms, unlike some competitors facing higher cancellation rates due to specific market exposures [85][86] Question: How is the company responding to the evolving pharma landscape? - Management noted a shift in customer willingness to move forward with trials, indicating a more stable operating environment following recent policy changes [87][89]

Core Insights - The article discusses the rapid growth and development of Nanjing Commer Biopharmaceutical Co., Ltd. (Commer Pharma), a Contract Research Organization (CRO) established in June 2020, which has expanded to over 500 employees and completed several hundred million yuan in financing [1][2] Group 1: Company Overview - Commer Pharma has been recognized as a "potential unicorn enterprise" in Jiangsu and has entered the "Future Star of Science and Technology" list in 2023 [1] - The company aims to provide comprehensive drug development services, addressing the inefficiencies in traditional CRO services that often involve single-step outsourcing [2][3] Group 2: Market Dynamics - The demand for innovative drug development is increasing due to healthcare cost control and centralized procurement policies, leading to a surge in outsourcing needs [3][6] - The global pharmaceutical industry is shifting towards China, creating a significant gap for CRO services that meet international regulatory standards [3][6] Group 3: Technological Capabilities - Commer Pharma has established nine specialized technology platforms, covering areas such as solid-state drug research and transdermal drug delivery systems, to create a full-service development loop from preclinical research to clinical trials [3][4] - The company employs a highly qualified team, with over 150 employees holding master's or doctoral degrees and more than 80% having over five years of experience in drug development [4] Group 4: Innovation and Problem Solving - Commer Pharma successfully addressed a complex challenge in developing a triple-combination drug for HIV, optimizing the formulation to reduce production costs by 10% while improving absorption rates [4][5] - The company emphasizes the need for innovative processes to enhance efficiency and reduce costs in drug development, particularly in the context of high standards for consistency evaluation [5] Group 5: Future Aspirations - Commer Pharma is constructing a GLP-compliant research headquarters to enhance its capabilities in non-clinical safety evaluations, aiming to support global multi-center clinical trials and facilitate market entry for clients in Europe and the U.S. [6][7] - The company aspires to become a globally competitive, one-stop innovative CRO platform, providing end-to-end solutions from target discovery to commercial production [7]

Summary of Charles River Laboratories Conference Call Company Overview - **Company**: Charles River Laboratories (NYSE: CRL) - **Industry**: Contract Research Organizations (CROs) Key Points Demand Environment - The company reported a net book-to-bill ratio of 0.82, unchanged from Q2, primarily due to a lull in biotech during Q3 [4][5] - There has been an improvement in bookings in biotech over the last few months, indicating a positive trend moving into the fall and winter [4][5] - Proposal volume in both biotech and global segments has been strong, providing confidence for future quarters [4] Pricing Strategy - Charles River holds approximately 30% market share in the safety assessment market, with competitors significantly smaller [7] - The company is strategically using pricing to maintain market share and attract new clients, especially in a softer demand environment [8][9] - Pricing has stabilized, with no significant headwinds anticipated in the safety assessment business [10] Discovery Services - Discovery services represent about 10% of the DSA segment and have been soft due to tight biotech funding [11] - The company expects a rebound in discovery services as biotech funding improves [11] Sales Strategy - The DSA business operates holistically, allowing for better utilization of resources and maximizing client wallet share [14][15] - The sales strategy is not heavily dependent on pull-through from discovery services due to the small size of the discovery segment [13] China Market Dynamics - About 30% of all programs are now in-licensed from China, which poses minimal preclinical work for Charles River [18] - The company is monitoring the trend of drug discovery moving to China and the competitive landscape with local providers [19][20] - Charles River is interested in both servicing Western companies and the domestic Chinese market, but is cautious due to geopolitical pressures [21] Non-Human Primate (NHP) Market - NHP shipments were pulled forward from Q4 to Q3, with stable supply chains established [22][23] - The company has closed investigations by the DOJ and SEC, indicating no concerns regarding animal welfare [24] Research Models Segment - North America has seen a decline in research model volumes, primarily driven by the biotech segment, while Europe and China have held up better [28][30] - The company believes that research model volumes will rebound with improved biotech funding [30] Cost-Saving Initiatives - Charles River announced an additional $70 million in cost savings, building on a previous $225 million initiative [31] - Cost-saving measures include site consolidations, efficiency improvements in G&A, and digital automation [31] Acquisition Strategy - The company has a clear roadmap for acquisitions, focusing on core business areas to enhance client wallet share, particularly in bioanalytical services and potential opportunities in China [36] Additional Insights - The company is committed to refining its service portfolio to remain competitive [12] - The strategic review may lead to share repurchases or acquisitions, depending on market conditions [34][36]